Sarepta Therapeutics, INC

Sarepta Therapeutics announces the appointment of Michael Severino, M.D. as Chief Executive Officer, succeeding Douglas Ingram, who will transition to a consulting role.

Sarepta Therapeutics stockholders approved the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan at the annual meeting.

Sarepta Therapeutics reported Q1 2026 financial results, with total revenues of $730.8 million, driven by strong PMO net revenues and advancements in its siRNA pipeline.

Sarepta Therapeutics, Inc. announced that CEO Douglas Ingram will retire by the end of 2026 or upon the appointment of his successor.

Sarepta Therapeutics announced its fourth quarter and full-year 2025 financial results, highlighting significant revenue growth for the year, strategic debt refinancing, and positive clinical advancements for its Duchenne muscular dystrophy therapies.

Sarepta Therapeutics announced preliminary Q4 and full-year 2025 net product revenues, exceeding its ELEVIDYS sales floor and reporting a strong cash position.

Sarepta Therapeutics announces Q1 2026 financial results, with significant revenue shifts and ongoing R&D focus.

Sarepta Therapeutics reports a significant net loss in Q3 2025, driven by ELEVIDYS shipment suspensions, a strategic restructuring, and a failed confirmatory trial for two PMO products.

Sarepta Therapeutics reported a net loss for the first half of 2025, driven by significant R&D investments and legal challenges, despite strong ELEVIDYS revenue growth.

Sarepta Therapeutics' Q1 2025 results showcase significant revenue growth driven by ELEVIDYS and the initiation of a major collaboration with Arrowhead Pharmaceuticals, alongside increased R&D spending.

Sarepta Therapeutics' Q3 2024 results show a significant increase in revenue, primarily driven by sales of ELEVIDYS, and a return to profitability.

Sarepta Therapeutics' Q2 2024 results show a significant increase in revenue driven by the launch of ELEVIDYS, despite a decrease in collaboration revenue.

Sarepta Therapeutics reported a significant net loss of $713.4 million in 2025, driven by increased R&D expenses for new collaborations and substantial inventory write-offs, alongside critical safety updates for ELEVIDYS and a primary endpoint miss in the ESSENCE trial.

Sarepta Therapeutics' 2024 10-K filing highlights significant revenue growth driven by ELEVIDYS, strategic collaborations, and ongoing development of genetic therapies for rare diseases.

Sarepta Therapeutics and Roche have further amended their licensing agreement for Sarepta's Duchenne muscular dystrophy gene therapy, SRP-9001, adjusting supply agreement deadlines.

Michael Severino, Chief Executive Officer and a Director of Sarepta Therapeutics, Inc., reported multiple transactions in common stock on July 28, 2026.

Sarepta Therapeutics director Kathryn Boor was granted 16,875 restricted stock units as part of an equity compensation award.

Sarepta Therapeutics director Stephen Mayo was granted 16,875 restricted stock units as part of standard equity compensation.

Director Hans Wigzell was granted 16,875 restricted stock units in Sarepta Therapeutics, Inc.

Sarepta Therapeutics director M. Kathleen Behrens was granted 16,875 restricted stock units as part of an equity compensation plan.

Sarepta Therapeutics director Deirdre Connelly was granted 16,875 restricted stock units as part of an equity compensation award.

Sarepta Therapeutics is seeking shareholder approval for new 2026 equity and stock purchase plans while managing a leadership transition following the announced retirement of CEO Douglas Ingram.

Sarepta Therapeutics has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

Sarepta Therapeutics is asking stockholders to approve amendments to its equity incentive and employee stock purchase plans to increase the number of shares available for issuance.

Sarepta Therapeutics' proxy statement details proposals for the 2024 annual meeting, including director elections, executive compensation approval, and auditor ratification, while also providing insights into the company's governance, executive compensation, and sustainability efforts.

Sarepta Therapeutics has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

Sarepta Therapeutics, Inc. has filed its quarterly 13F holdings report for the period ending March 31, 2026, detailing its investment positions.

Sarepta Therapeutics and its investment arm have fully divested their holdings in Arrowhead Pharmaceuticals through a private sale and a share redemption.

Sarepta Therapeutics Investments, a subsidiary of Sarepta Therapeutics, has acquired a 9.5% stake in Arrowhead Pharmaceuticals for $325 million, formalizing a strategic collaboration and gaining board representation.

Vanguard Portfolio Management has reported a significant beneficial ownership stake of 8.05% in Sarepta Therapeutics Inc., as of June 30, 2026.

Vanguard Capital Management has reported a beneficial ownership of 5.11% in Sarepta Therapeutics Inc. common stock as of March 31, 2026.

Vanguard Portfolio Management has reported beneficial ownership of 6.43% of Sarepta Therapeutics' common stock as of March 31, 2026.

The Vanguard Group has amended its Schedule 13G filing for Sarepta Therapeutics, reporting 0% beneficial ownership due to an internal reporting realignment.

AQR Capital Management, LLC and its parent entity have reported a beneficial ownership of 7.73% in Sarepta Therapeutics, Inc., totaling 8,104,869 shares.

BlackRock, Inc. has reported a 12.6% beneficial ownership stake in Sarepta Therapeutics Inc., holding 13,232,652 shares of common stock as of December 31, 2025.